Haematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease

J Clin Med. 2023 Sep 20;12(18):6083. doi: 10.3390/jcm12186083.

Abstract

Chronic granulomatous disease (CGD) is an inborn error of immunity due to defects in the transport or function of subunits of nicotinamide adenine dinucleotide phosphate oxidase, the enzyme that generates the phagocyte respiratory burst responsible for intracellular killing of engulfed micro-organisms. Patients present with infectious or inflammatory complications. Common bacterial pathogens include Staphylococcus aureus and Burkholderia cepacia complex. Fungal pathogens include Aspergillus species, particularly Aspergillus fumigatus. Inflammatory complications most commonly manifest as inflammatory bowel disease or lung disease. Granulomata are the distinguishing histological feature. Haematopoietic stem cell transplantation (HSCT) was first considered for CGD in the early 1970's. Since then, refinements in transplant technique, donor selection, conditioning regimens, and graft engineering have widened the option of HSCT to most patients with CGD. This review charts the progress made in HSCT for CGD.

Keywords: T-lymphocyte depletion; chronic granulomatous disease; haematopoietic stem cell transplantation; treosulfan.

Publication types

  • Review

Grants and funding

This research received no external funding.